| Dayneka is a clinical specialist with the Pharmacy Department of the tertiary care pediatric teaching hospital [[Children's Hospital of Eastern Ontario]] (CHEO).((//Natalie Dayneka - Clinical Specialist and.. - CHEO.// ZoomInfo. Retrieved April 19, 2022, from https://web.archive.org/web/20220419191517/https://www.zoominfo.com/p/Natalie-Dayneka/87864102)) She was a co-author of the online 2015 CHEO Antimicrobial Guidelines for Children which has been offered externally as a mobile application (APP) for pediatric practitioners across Canada. | Dayneka is a clinical specialist with the Pharmacy Department of the tertiary care pediatric teaching hospital [[Children's Hospital of Eastern Ontario]] (CHEO).((//Natalie Dayneka - Clinical Specialist and.. - CHEO.// ZoomInfo. Retrieved April 19, 2022, from https://web.archive.org/web/20220419191517/https://www.zoominfo.com/p/Natalie-Dayneka/87864102)) She was a co-author of the online 2015 CHEO Antimicrobial Guidelines for Children which has been offered externally as a mobile application (APP) for pediatric practitioners across Canada. |
| She has consulted on various federal committees and was a member of the Pharmacology and Therapeutics Committee for the [[First Nations and Inuit Health Programs Directorate]]. She also served on the [[Canadian Paediatric Society]]'s Drug Therapy and Hazardous Substances Committee. More recently, she served on the Ontario Quality Based Procedure Tonsillectomy Clinical Expert Advisory Group.((//Paediatric Tonsillectomy with and without Adenoidectomy QBP Clinical Expert Advisory Group.// (2015, July). Wayback Machine; Provincial Council for Maternal and Child Health. https://web.archive.org/web/20210304094328/https://www.pcmch.on.ca/wp-content/uploads/2015/07/QBP_Tonsillectomy_Membership.pdf)) | She has consulted on various federal committees and was a member of the Pharmacology and Therapeutics Committee for the [[First Nations and Inuit Health Programs Directorate]]. She also served on the [[Canadian Paediatric Society]]'s Drug Therapy and Hazardous Substances Committee. CPS receives funding through sponsorships by [[pharmaceutical_companies:Abbott]], [[pharmaceutical_companies:AstraZeneca]], [[Canadian Institutes for Health Research]], [[pharmaceutical_companies:Elvium Life Sciences]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Johnson & Johnson]], [[pharmaceutical_companies:Medexus Pharma]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pendopharm]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sanofi Genzyme]], and [[pharmaceutical_companies:UltraGenyx]].((Canadian Paediatric Society. //Thank our partners.// 98th Annual Conference | Canadian Paediatric Society. Retrieved April 19, 2022, from https://archive.ph/Sq1DQ)) |
| In 1993, Dayneka received research funding from the [[National Institute of General Medicine Services]] (NIGMS) under the [[National Institutes of Health]] (NIH).((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691)) | In 1993, Dayneka received research funding from the [[National Institute of General Medicine Services]] (NIGMS) under the [[National Institutes of Health]] (NIH).((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691)) She disclosed engaging in consulting activities for [[pharmaceutical_companies:Gilead Sciences]] and [[pharmaceutical_companies:Janssen]].((Kreutzwiser, D., Sheehan, N., Dayneka, N., Lemire, B., Wong, A., Samson, L., & Brophy, J. (2016). //Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV.// Antiviral Therapy, 22(6), 545–549. https://doi.org/10.3851/imp3139)) Further research was funded by [[pharmaceutical_companies:AstraZeneca]], [[medical_technology_companies:Cook]], and [[pharmaceutical_companies:Covidien]].((Stewart, P., Dayneka, N., Grenier, S., Stewart, C., Beadow, L., Joseph, G., Mack, D., & Vaillancourt, R. (2009). //In Vitro Study of Esomeprazole Sachet Suspension Administered via Enteral Feeding Tubes.// The Canadian Journal of Hospital Pharmacy, 62(1). https://doi.org/10.4212/cjhp.v62i1.122)) |
